Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
InChi: InChI=1S/C22H21N8O8PS4
PubMed PMID: 27181927
486427-17-2
SGC0946 was used at 1-5 µM final concentration in vitro and in cellular assays
or dexamethasone triggered synergistic anti-MM activity
MLN-9708 - CAS# 1239908-20-3 60262 InChi: InChI=1S/C22H21N8O8PS4MLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved
US$ 38.00
US$ 38.00
US$ 29.00
US$ 118.00
US$ 85.00
US$ 38.00
US$ 88.00
US$ 38.00
US$ 38.00
US$ 38.00